RIPK1 and neoplasm: Taken together, these results show that RIPK1 or RIPK3-deficient ECs fail to respond to tumor-induced vascular permeability or VEGF-A-induced permeability and angiogenesis, resulting in a defect in B16-F10 transendothelial migration.